ContraFect

OverviewSuggest Edit

ContraFect is a clinical stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. The Company's most advanced product candidates are CF-301, a lysin for the treatment of Staph aureus bacteremia and CF-404, a cocktail of monoclonal antibodies for the treatment of life-threatening seasonal and pandemic varieties of influenza.

TypePublic
Founded2008
HQYonkers, NY, USMap
Websitecontrafect.com
Employee Ratings2.5More
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Mar 2020)24(+20%)
Revenue (FY, 2017)$0
Share Price (Mar 2021)$5.4 (+3%)
Cybersecurity ratingAMore

Key People/Management at ContraFect

Roger J. Pomerantz

Roger J. Pomerantz

President, Chief Executive Officer and Chairman of the Board
David N. Low

David N. Low

Director
Michael J. Otto

Michael J. Otto

Director
Cary W. Sucoff

Cary W. Sucoff

Director
Cara Cassino

Cara Cassino

Chief Medical Officer and Executive Vice President of Research and Development
Sol Barer

Sol Barer

Lead Director
Show more

ContraFect Office Locations

ContraFect has an office in Yonkers
Yonkers, NY, US (HQ)
28 Wells Ave
Show all (1)

ContraFect Financials and Metrics

ContraFect Revenue

USD

Net income (Q2, 2020)

(17.6m)

EBIT (Q2, 2020)

(8.2m)

Market capitalization (1-Mar-2021)

149.3m

Closing stock price (1-Mar-2021)

5.4

Cash (30-Jun-2020)

30.8m

EV

122.3m
ContraFect's current market capitalization is $149.3 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

General and administrative expense

8.1m10.1m11.4m9.2m8.7m9.8m

R&D expense

8.9m15.0m22.1m17.3m22.4m18.1m

Operating expense total

16.9m25.1m33.5m26.6m31.1m27.9m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

General and administrative expense

1.2m2.3m2.3m2.9m2.4m4.7m2.5m1.9m2.1m2.3m1.8m2.2m2.1m2.3m2.6m2.4m3.0m2.6m

R&D expense

1.5m2.4m2.4m4.3m3.4m4.4m7.3m5.9m4.2m3.8m4.9m5.3m5.7m4.1m4.8m5.3m5.1m5.5m

Operating expense total

2.7m4.6m4.7m7.2m5.7m9.2m9.8m7.9m6.3m6.1m6.7m7.5m7.8m6.4m7.4m7.6m8.1m8.2m

EBIT

(2.7m)(4.6m)(4.7m)(7.2m)(5.7m)(9.2m)(9.8m)(7.9m)(6.3m)(6.1m)(6.7m)(7.5m)(7.8m)(6.4m)(7.4m)(7.6m)(8.1m)(8.2m)
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

25.7m10.0m3.8m7.0m8.3m24.2m

Prepaid Expenses

368.8k1.2m1.0m1.8m988.8k6.6m

Current Assets

27.8m34.1m36.2m48.7m31.4m30.8m

PP&E

2.1m1.6m1.3m1.1m1.1m1.1m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

2.2m31.3m12.4m23.6m20.8m7.6m10.6m10.7m4.7m4.9m4.3m4.6m11.0m6.8m7.4m10.5m10.6m30.8m

Prepaid Expenses

248.3k417.1k271.7k1.1m946.0k1.1m1.5m1.1m1.5m2.2m1.3m2.2m1.8m2.1m2.0m2.3m5.6m5.3m

Current Assets

2.4m31.7m23.2m36.3m30.4m27.4m20.6m44.4m30.3m23.9m53.8m35.5m39.4m25.1m16.2m12.8m22.3m45.0m

PP&E

2.5m2.3m2.0m1.9m1.7m1.5m1.5m1.3m1.2m1.2m1.1m1.1m1.1m1.2m1.2m1.1m1.1m1.0m
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(30.1m)(25.1m)(28.5m)(15.5m)(37.7m)(12.8m)

Depreciation and Amortization

551.3k537.3k451.0k187.2k151.3k169.2k

Accounts Payable

(1.1m)600.4k649.0k324.2k1.1m(444.7k)

Cash From Operating Activities

(14.9m)(22.2m)(29.3m)(24.5m)(26.3m)(27.4m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(9.0m)(25.4m)(4.9m)(12.0m)(17.5m)(8.9m)(18.6m)(29.1m)(6.3m)(9.2m)(10.8m)(39.2m)(43.6m)11.6m2.9m(2.4m)(7.6m)(25.2m)

Depreciation and Amortization

279.3k414.7k134.3k268.7k403.0k134.4k268.9k385.0k45.6k91.1k133.0k71.1k110.3k42.0k84.4k126.8k42.4k84.7k

Accounts Payable

490.0k(1.6m)(491.4k)559.7k(420.2k)1.2m3.5m2.7m8.7k(787.3k)(1.5m)52.6k770.7k(453.1k)(2.5m)1.3m(1.2m)(4.2m)

Cash From Operating Activities

(4.9m)(11.0m)(4.5m)(10.4m)(16.3m)(6.5m)(13.5m)(21.3m)(6.2m)(13.2m)(19.2m)(13.2m)(19.2m)(7.3m)(16.1m)(19.8m)(7.5m)(17.7m)
show all
USDQ2, 2014

Debt/Equity

-0.2 x

Debt/Assets

1.5 x

Financial Leverage

-0.1 x
Show all financial metrics

ContraFect Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

Learn more about our premium products
SecurityScorecard logo

ContraFect Online and Social Media Presence

ContraFect's Trends

Embed Graph

ContraFect News and Updates

February 11, 2021

ContraFect Announces Appointment of Dr. Jane F. Barlow to Board of Directors

YONKERS, N.Y., Feb. 11, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs) as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, tod…
November 13, 2020

ContraFect Reports Third Quarter 2020 Financial Results and Provides Business Update

CARB-X and Cystic Fibrosis Foundation grants provide significant additional funding to advance CF-370 for Pseudomonas aeruginosa infections
August 25, 2020

ContraFect Announces Funding Agreement with the Cystic Fibrosis Foundation

Initial evaluation of Direct Lytic Agents (DLAs) as potential novel modalities to address lung infections caused by antibiotic-resistant Gram-negative bacterial pathogens in Cystic Fibrosis Initial evaluation of Direct Lytic Agents (DLAs) as potential novel modalities to address lung infections caus…
August 14, 2020

ContraFect Reports Second Quarter 2020 Financial Results and Provides Business Update

Exebacase Phase 2 study results published in the Journal of Clinical Investigation
July 20, 2020

ContraFect Announces up to $18.9 Million in Funding from CARB-X to Support Acceleration of the CF-370 Program for Treating Pseudomonas aeruginosa Infections towards Clinical Stage Development

YONKERS, N.Y., July 20, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatenin…
June 17, 2020

Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation

Phase 2 study results demonstrated the potential clinical benefit of exebacase, when used in addition to existing antibiotics, for the treatment of life-threatening MRSA bacteremia
Show more

ContraFect Blogs

September 25, 2018

ContraFect to Present at the “Exploring the Antibiotic Pipeline 2018” Symposium and also to Present New Data on CF-301 (exebacase) at IDWeek 2018

YONKERS, N.Y., Sept. 25, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced the Company will p…
September 06, 2018

ContraFect Completes Enrollment in Phase 2 Clinical Trial Evaluating CF-301 (exebacase) in Patients with Staphylococcus Aureus Bacteremia

Company remains on track to announce top-line results in Q4 2018 YONKERS, N.Y., Sept. 06, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug…
August 14, 2018

ContraFect to Participate in FDA Workshop on Development of Non-Traditional Therapies for Bacterial Infections

YONKERS, N.Y., Aug. 14, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Cara Cassino, …
July 26, 2018

ContraFect Corporation Announces Proposed Public Offering of Common Stock

YONKERS, N.Y., July 26, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that it has commenced an underwrit…
June 14, 2018

ContraFect to Present at JMP Securities Life Sciences Conference

YONKERS, N.Y., June 14, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Cara Cassino, …
May 30, 2018

ContraFect to Present New Data on CF-301 (exebacase) and Lysins Targeting Gram-Negative Pathogens at ASM Microbe 2018

YONKERS, N.Y., May 30, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced the presentation of …

 ContraFect Frequently Asked Questions

  • When was ContraFect founded?

    ContraFect was founded in 2008.

  • Who are ContraFect key executives?

    ContraFect's key executives are Roger J. Pomerantz, David N. Low and Michael J. Otto.

  • How many employees does ContraFect have?

    ContraFect has 24 employees.

  • Who are ContraFect competitors?

    Competitors of ContraFect include Xcell Biosciences, Abcam and TxCell.

  • Where is ContraFect headquarters?

    ContraFect headquarters is located at 28 Wells Ave, Yonkers.

  • Where are ContraFect offices?

    ContraFect has an office in Yonkers.

  • How many offices does ContraFect have?

    ContraFect has 1 office.